Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant glandular epithelial neoplasm characterized by the presence of clear and hobnail cells. It is highly associated with ovarian endometriosis, pelvic endometriosis and paraendocrine hypercalcemia.
Biomarker and diagnostic research for ovarian clear cell adenocarcinoma has been reported in the published literature.
18 clinical trials registered, 7 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 3 PHASE3, 8 PHASE2, 6 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04919629](https://clinicaltrials.gov/study/NCT04919629) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 6:22 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion |
PHASE2 |
Roswell Park Cancer Institute |
RECRUITING |
[NCT05950464](https://clinicaltrials.gov/study/NCT05950464) | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
[NCT06639074](https://clinicaltrials.gov/study/NCT06639074) | Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | PHASE2 | Mayo Clinic | RECRUITING |
[NCT05039801](https://clinicaltrials.gov/study/NCT05039801) | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | PHASE1 | M.D. Anderson Cancer Center | RECRUITING |
[NCT05231122](https://clinicaltrials.gov/study/NCT05231122) | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | PHASE2 | Roswell Park Cancer Institute | RECRUITING |
40 publications have been identified in PubMed for ovarian clear cell adenocarcinoma. Research spans Case Report / Case Series (43%), Diagnostic / Biomarker (15%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 43% |
Testing and diagnosis research | 6 | 15% |
Clinical study results | 5 | 13% |
Laboratory research | 5 | 13% |
Research summaries | 3 | 8% |
Disease patterns and progression | 3 | 8% |
Other research | 1 | 3% |
PLOS One Editors (2026). [PMID: 41701672](https://pubmed.ncbi.nlm.nih.gov/41701672/). *PLoS One*. [Other]
Abe T (2026). [PMID: 41171408](https://pubmed.ncbi.nlm.nih.gov/41171408/). *Abdom Radiol (NY)*. [Diagnostic / Biomarker]
Kissinger CR (2026). [PMID: 41593408](https://pubmed.ncbi.nlm.nih.gov/41593408/). *Journal of cancer research and clinical oncology*. [Case Report / Case Series]
Narusawa Y (2026). [PMID: 42211942](https://pubmed.ncbi.nlm.nih.gov/42211942/). *Case Rep Pathol*. [Case Report / Case Series]
Li CL (2026). [PMID: 41957787](https://pubmed.ncbi.nlm.nih.gov/41957787/). *J Ovarian Res*. [Case Report / Case Series]
Büyücek S (2026). [PMID: 41519763](https://pubmed.ncbi.nlm.nih.gov/41519763/). *BMC cancer*. [Diagnostic / Biomarker]
Chae YK (2026). [PMID: 41672597](https://pubmed.ncbi.nlm.nih.gov/41672597/). *Journal for immunotherapy of cancer*. [Clinical Trial Publication]
Gaia-Oltean AI (2025). [PMID: 40804901](https://pubmed.ncbi.nlm.nih.gov/40804901/). *Diagnostics (Basel, Switzerland)*. [Clinical Trial Publication]
Devins KM (2025). [PMID: 40680852](https://pubmed.ncbi.nlm.nih.gov/40680852/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Case Report / Case Series]
Shimizu K (2025). [PMID: 40024277](https://pubmed.ncbi.nlm.nih.gov/40024277/). *Clinica chimica acta; international journal of clinical chemistry*. [Diagnostic / Biomarker]
AI-curated news mentioning ovarian clear cell adenocarcinoma
Updated Mar 4, 2026
A multi-institutional study provides clinical and molecular insights into clear cell adenocarcinoma of the urinary tract. This research enhances understanding of the disease's characteristics, potentially guiding future therapeutic strategies.
A case report highlights primary clear cell adenocarcinoma of the female urethra, a rare disease with limited documented cases. This report contributes to the understanding of this uncommon malignancy.